tbuckley/cabot-search huggingface dataset:
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
Authors: Nils Homann, Sylvie Lorenzen, Michael Schenk, Peter C. Thuss-Patience, Eray Goekkurt, Ralf Dieter Hofheinz, Albrecht Kretzschmar, Claus Bolling, Stefan Angermeier, Andreas Wicki, Alexander Rheinhard Siebenhuener, Udo Lindig, Daniel Pink, Thomas Jens Ettrich, Harald Schmalenberg, Lisa Waberer, Jonathan Talbot, Claudia Pauligk, Thorsten Oliver Goetze, Salah-Eddin Al-Batran
Journal: Journal of Clinical Oncology (2020)

4549 Background: The DANTE study evaluates atezolizumab in the perioperative treatment of locally advanced, potentially resectable gastric or GEJ adenocarcinoma in combination with perioperative FLOT. Here, we report the protocol-defined interim safety analysis. Methods: DANTE is a multinational, prospective, multicenter, randomized, investigator-initiated, open label phase II trial. Patients (pts) with locally advanced, potentially resectable adenocarcinoma of the stomach and GEJ (≥cT2 and/or N-positive) without distant metastases are enrolled. Pts are randomized 1:1 to 4 pre-operative 2-week cycles of FLOT followed by surgery and 4 additional cycles of FLOT plus atezolizumab at 840 mg every 2 weeks, followed by a total of 8 additional cycles of atezolizumab at 1200 mg every 3 weeks as monotherapy (arm A) or FLOT alone (arm B). Primary endpoint is time to disease progression or relapse after surgery (PFS/DFS). Results: Recruitment started in Sep 2018; by Feb 2020, a total of 175 pts have been randomized. This analysis is based on the first 40 pts (20 pts in each arm). The pts had a median age of 62 y and 75% of pts had an ECOG PS of 0 in both arms. The cohort was well balanced in terms of tumor location and clinical stage. 5% of the 40 patients (overall 7.4% of 175 pts enrolled) showed microsatellite instability. 90% of pts enrolled completed all pre-operative cycles in each arm. Total number of adverse events with relation to study treatment was 154 in arm A and 148 in arm B. Total number of serious adverse events (SAE; related or not) was 16 in Arm A and 14 in arm B. 20% of pts in each arm had an SAE due to perioperative morbidity. No surgical mortality was observed. 18 and 19 pts proceeded to operation in arms A and B, respectively. Premature treatment discontinuation occurred in 2 pts in each arm: disease progression (1) and deterioration of general health condition (1) in arm A; and pts’ wish (1) and death (1) in arm B. Median hospitalization time was 15 days in arm A and 16 days in arm B. Conclusions: Perioperative atezolizumab plus FLOT is feasible and safe. The study continues recruitment. Clinical trial information: NCT03421288 .
反复咳嗽、咳痰、喘憋30余年,加重伴发热一天
Authors: 夏秀萍, 沈志萍, 桂红芝, 王红英, 祝墡珠
Journal: BMJ (2012)

病史摘要患者,男性,87岁.因反复咳嗽、咳痰、喘憋30余年,加重伴发热一天于2011年7月31日入院.患者反复咳嗽、咳痰、喘憋30余年,以冬季发作为重,自服抗感染止咳药物可好转,近10余年来发作频繁.近六七年出现活动后气急,休息后好转,双下肢出现反复浮肿,曾多次于我院及嘉定中心医院就诊,诊断为慢性支气管炎(慢支)、肺气肿、肺源性心脏病(肺心病),予以抗炎、平喘、化痰、利尿等治疗后病情稳定。
Plasma brain natriuretic peptide/N-terminal pro-brain natriuretic peptide ratio reflects the severity of pulmonary infection in patients with heart failure
Authors: Hong Zhou, Qiumei Cao
Journal: BMJ (2014)

Eighty two heart failure (HF) patients were enrolled in the study, including 52 cases with pulmonary infection (infectious group) and 30 cases without pulmonary infection (noninfectious group). Plasma brain natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were measured and the correlation of plasma BNP, NT-proBNP and NT-proBNP/BNP with inflammatory markers (WBC count, CRP, PCT) and left ventricular ejection fraction (LVEF) was analyzed.Results show that NT-proBNP/BNP ratio in infectious group was significantly higher than that in noninfectious group (t=10.764, P 0.05); NT-proBNP and BNP levels were not correlated with inflammation markers and LVEF (P>0.05). In noninfectious group, NT-proBNP/BNP was not correlated with inflammation markers and LVEF (P>0.05), NT-proBNP and BNP were positively correlated with CRP and negatively correlated with LVEF (all P 0.05). Multiple linear regression analysis showed that NT-proBNP/BNP ratio had positive correlation with CRP in infectious group. The results reveal that in heart failure patients complicated with pulmonary infection, neither NT-proBNP nor BNP reflects the severity of heart failure or infection; but the NT-proBNP/BNP ratio can indicate the severity of infection independently.


Key words: 
Natriuretic peptide, brain; Heart failure
Management and prevention for shoulder dystonia
Authors: 王廷涛, 高孝斗, 高清梅
Journal: BMJ (2006)

肩难产(shoulder dystocia,SD)是一种危急的分娩并发症,近20年来,其发生率有上升趋势[1].随着围生医学的发展及产前保健的加强,妊娠合并症及妊娠并发症如妊娠高血压疾病、胎儿发育迟缓、胎儿窘迫等导致的围生期母儿并发症减少,而SD导致的母儿危害及由此引发的医疗纠纷日益凸现出来,作者从优生观点出发,复习有关文献,综述重点在SD的发生率、高危因素、并发症、处理及预防等方面。
Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis <i>et al</i>
Authors: Hendrik Schulze-Koops, Klaus Krueger, Christof Specker
Journal: Annals of the Rheumatic Diseases (2020)

We read with interest the study of Fragoulis et al 1 about treatment adherence and behaviour changes of patients with autoimmune inflammatory rheumatic diseases (AIRD) in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 pandemic. In their study, only 11 out of the 500 patients with AIRD interviewed had discontinued antirheumatic treatment solely due to fear of immunosuppression, for example, for fear of an increased risk for SARS-CoV-2 infection. This is reassuring to note as interruption of clinically efficacious therapy in AIRD is associated with an increased risk of relapse2 which might lead to the necessity of intensifying immunosuppressive therapy, possibly beyond the original level. For this very apprehension and also for the accumulating cautious impression that patients with rheumatological diseases might not have a worse prognosis during COVID-19,3 4 …
Next generation sequencing reveals CCNE1 amplification as an independent prognostic factor for triple negative breast cancer (TNBC) patients.
Authors: Xin Huang, Huanwen M. Wu, Changbin Zhu, Di Shao, Dan Guo, Yidong Zhou, Yan Lin, Chang Chen, Ying Xu, Bin Zhao, Yu Song, Tao Lu, Qiang Sun
Journal: Journal of Clinical Oncology (2020)

558 Background: Triple negative breast cancer (TNBC) has the worst prognosis among breast cancer due to the heterogeneity as well as lack of better therapeutic approach. It remains controversial whether BRCA status is the predictor of survival in TNBC. Besides, both germline and somatic mutation may contribute to the prognosis. This study is to explore the potential predictors and therapeutic targets based on genetic data and clinicopathological parameters. Methods: Seventy-five TNBC patients were enrolled with approximately 2:1 based on BRCA status. Genetic data was analysed by comprehensive genomic profiling 508 key cancer related genes. DAVID was applied to perform pathway enrichment analysis of significant enriched genetic alterations. Cox regression model was applied to evaluate disease-free survival (DFS) and overall survival (OS). Immuno-chemistry (IHC) was used to validate clinically meaningful genetic alteration. Results: In this study, 27 germline mutations were detected, including 26 homologous recombination repair (HRR) pathway gene mutations and 1 mismatch repair gene mutation among them 16 BRCA1 mutations and 5 BRCA2 mutations were found. Germline HRR including BRCA1/2 mutation marginally affected DFS ( p = 0.0624 and 0.15, respectively). We found 480 somatic genetic alterations including 110 copy number variations (CNV). The median value of TMB was determined to be 4.1 Muts/Mb which divided 74 TNBC patients into TMB-low (TMB-l) and TMB-high (TMB-h) group. TMB-l group had inferior DFS to TMB-h ( p = 0.0457). CCNE1 (with 5% frequency) copy number gain was specifically enriched in TMB-l group but mutually exclusive with BRCA1/2 mutation. TNBC with CCNE1 gain displayed worse DFS ( p&lt; 0.0001). Cox multivariate regression analysis indicated CCNE1 gain was an independent risk factors for DFS [HR = 13.48 (95% CI 2.62-69.23), p= 0.002)]. Pathway analysis indicated CCNE1 harmed prognosis through regulation of transcription in G1/S phase. Expression of cyclin E1 was validated by IHC, which would be presented later. Conclusions: Comprehensive genomic profiling disclosed various potential prognostic markers for TNBC by integrating clinical characters. Especially, amplified CCNE1 may be a potential prognostic marker and therapeutic target. [Table: see text]
Real-world dosing, management, and clinical outcomes of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan.
Authors: Laith I. Abushahin, Paul Cockrum, Andy Surinach, Bruce Belanger
Journal: Journal of Clinical Oncology (2020)

e16780 Background: Pancreatic cancer remains one of the most lethal cancers in the United States (US) with a 5-year relative survival of 10%. Liposomal irinotecan is a topoisomerase inhibitor indicated, in combination with 5-fluorouracil and leucovorin, for pts with mPDAC following disease progression on gemcitabine-based therapy. This study examines the real-world use and therapeutic management of pts with mPDAC treated with liposomal irinotecan. Methods: This retrospective observational study utilized the Flatiron Health EHR-derived de-identified database from over 280 cancer clinics in the US. Data were analyzed for adult pts with mPDAC treated with liposomal irinotecan based regimens between Nov 2015 and Oct 2019. Pts were categorized into two starting dose groups: 70mg/m 2 and &lt; 65mg/m 2 . Pt characteristics, overall survival (OS), duration of treatment (DOT), and impact of dose reductions (DR, reduction ≥ 7mg/m 2 ) were assessed among pts who received ≥3 cycles of treatment (tx). Results: Of the 532 pts (median age: 69y, IQR: 62-75) included in the study, 95 (18%) had an ECOG score of 2+ at tx initiation. Of the 184 pts (69y, 42 – 84) that did not receive 3 cycles of tx, 47 (25%) had an ECOG score of 2+ and 83 (45%) had two or more prior lines of tx. 348 pts (69y, 43 – 85) received ≥3 cycles of tx. 116 (33%) pts had two or more prior lines of tx, 209 (60%) had an ECOG score of 0-1, 48 (14%) had an ECOG score of 2+, and 91 (26%) had missing scores. 220 (63%) initiated tx at 70mg/m 2 and 128 (37%) initiated at &lt; 65mg/m 2 . 83 (38%) 70mg/m 2 and 26 (20%) &lt; 65mg/m 2 pts experienced a DR during tx. 43 (52%) and 14 (54%) of the DRs occurred within the first 6 wks of tx in the 70mg/m 2 and &lt; 65mg/m 2 cohorts, respectively. Median DOT was 12.6 weeks for 70mg/mg 2 and 9.1 wks for &lt; 65mg/m 2 pts; DOT was longer among pts with a DR: 19.0 wks and 16.1 wks, respectively. Median OS (mOS) was 7.2 months (95% CI: 6.2 – 8.1) and 6.2 mos (5.0 – 7.4) for pts receiving 70mg/m 2 and &lt; 65mg/m 2 , respectively. mOS for pts with a DR was 8.9 mos (7.3 – 10.8) and 7.7 mos (5.0 – 14.9) for pts receiving 70mg/m 2 and &lt; 65mg/m 2 , respectively. mOS for pts with no DR was 6.0 mos (4.8 – 7.2) and 6.0 mos (4.7 - 7.2) for those receiving 70mg/m 2 and &lt; 65mg/m 2 , respectively. Conclusions: In this descriptive study among pts who were able to receive ≥3 cycles of liposomal irinotecan and remain on tx for ≥4 wks, DRs were effective in extending DOT and OS, independent of starting dose. The longest DOT and OS were observed in the pts who received 70mg/m 2 with DRs. Pts who received 70mg/m 2 and &lt; 65mg/m 2 had similar OS in the absence of DRs.
耳声发射及扩展高频测听在噪声性听力损失早期监测中的应用
Authors: 彭建华, 黄治物, 陶泽璋, 朱素琴
Journal: BMJ (2007)

采用畸变产物耳声发射、扩展高频测听及常频纯音测听对3组青年人(对照组、听阈正常组和听阈异常组)的听力进行检测.结果 显示听力正常组及听力异常组扩展高频听阈高于对照组,其扩展高频听阈引出率下降;听力异常组畸变产物耳声发射幅值在0.75～8.00 kHz均低于对照组.扩展高频测听及畸变产物耳声发射与常规纯音测听相比可灵敏地反应耳蜗受到的早期损害。
如何把好急诊急救的第一关
Authors: 萨木嘎
Journal: BMJ (2012)

急诊科担负着院前急救、院内急诊、危重患者监护的工作,医务人员工作量大、风险高,压力大.这些特点决定了对急诊科医生的思维过程要做出相应调整.1.识别患者死亡的可能性有多大:虽然绝大多数急诊患者不是危重病患者,但在应诊之初就凭表象主观地认为没什么大问题是草率和危险的.建议一开始就从患者是否会死亡的极端高度考虑,保持相当的警觉性,将患者分为3类:①高度可能性:即危重患者,必须立即给予医疗干预.②中度可能性:即一般急症患者,占急诊大多数,短时间内没有生命危险,但不可掉以轻心.③低度可能性:即非急症患者,病情稳定,可以稍缓处理。
Percutaneous packet-suturing for tunnel bleeding in endoscopic thyroidectomy via thoracic and mammary approach
Authors: Haibo Chen, Hai'ou Qu
Journal: BMJ (2016)

The clinical data of 192 patients undergoing endoscopic thyroidectomy via thoracic and mammary approach from June 2010 to July 2015 were retrospectively analyzed.Tunnel bleeding occurred in 11 cases (hemorrhage group), which was associated with the incorrect level of puncture(P<0.01). The tunnel bleeding was stopped by percutaneous packet-suturing in all 11 cases.There were no significant differences in postoperative drainage[(65.4±7.5) and (63.8±7.1) ml], subcutaneous petechiae[1/11 and 1.1%(2/181)], nursing costs[(135±20) and(132±16) yuan], postoperative hospital stay[(4.5±1.6) and (4.4±1.3) d] and rehemorrhage[0/11 and 0.6%(1/181)] between hemorrhage and non-hemorrhage groups.The results show that percutaneous packet-suturing is reliable and effective method for tunnel bleeding without additional postoperative complications.


Key words: 
Thyroidectomy; Laparoscope; Tunnel bleeding
Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
Authors: Paz J. Vellanki, Shanthi Marur, Pradeep Bandaru, Pallavi Shruti Mishra-Kalyani, Kunthel By, Andrew Girvin, Somak Chatterjee, Harpreet Singh, Patricia Keegan, Erin A. Larkins, Frank Cross, Richard Pazdur, Marc R. Theoret
Journal: Journal of Clinical Oncology (2020)

6509 Background: Recent evidence suggests that treatment with systemic antibiotics (Abx) disrupts the intestinal microbiome and may be associated with decreased survival for patients receiving treatment with ICIs for advanced cancers, including R/M HNSCC. However, a potential confounder is that Abx use identifies a subgroup of patients with a worse prognosis. The FDA examined the association between Abx use and survival for ICIs and other drugs used for the treatment of patients with R/M HNSCC. Methods: Data submitted to the FDA from three randomized controlled trials with ICI as a single agent or with chemotherapy (ICI group) compared to chemotherapy and/or cetuximab (Control group) were pooled. The association between systemic Abx use within 30 days of initiating anticancer therapy and survival for the ICI and Control groups was evaluated using Kaplan-Meier (KM) estimates and compared using Cox proportional hazards regression models, controlling for ECOG performance status, line of therapy, HPV status, PD-L1 expression, and other important prognostic factors. Results: In the ICI and Control groups, 36% and 46% of patients received Abx, respectively. For the ICI group, the difference in KM-estimated median overall survival (OS) was 5.6 months based on receipt of Abx (hazard ratio [HR] 1.70). Abx had no impact on OS for the Control group. Similar trends were observed for progression-free survival (PFS). Conclusions: In this exploratory analysis, systemic Abx within 30 days of initiating treatment for R/M HNSCC was associated with decreased survival for patients treated with ICIs compared with patients who did not receive Abx. Use of Abx had no apparent difference in survival in the control group. Further examination of the association between Abx use and clinical outcomes for patients with R/M HNSCC treated with ICIs is needed. [Table: see text]
Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).
Authors: Maria E. Cabanillas, Ramona Dadu, Renata Ferrarotto, Suyu Liu, Bryan M. Fellman, Neil D. Gross, Maria Gule-Monroe, Charles Lu, Horiana Grosu, Michelle D. Williams, Dzifa Yawa Duose, Saradhi Mallampati, Shannon Dervin, Edward Francis Mckenna, Rui Jennifer Wang, Mark Zafereo, Naifa Lamki Busaidy
Journal: Journal of Clinical Oncology (2020)

6514 Background: ATC is a rare/aggressive cancer with dismal outcome. Dabrafenib/trametinib is approved for BRAF-mutated ATC but pts eventually develop resistance. There are no approved drugs for pts with BRAF-wild type ATC. Better treatments (tx) are needed. Methods: ATC pts with PS &lt; 3 enrolled on a prospective trial at a single center, and tx was assigned by driver mutation: BRAF (cohort 1), RAS, NF1, or NF2 (cohort 2), or none of these (cohort 3). Cohort 4 with paclitaxel was exploratory for pts who did not qualify for 1-3. All pts received atezolizumab (A) IV + targeted therapy. Cohort 1 had run-in with vemurafenib (V) 960mg BID/cobimetinib (C) 60mg QD po for 28 days, followed by A 840mg Q2 weeks, at which time V dose was decreased to 720mg BID. Cohort 2: A + C (same doses as cohort 1); cohort 3: A 1200 mg Q3 weeks + bevacizumab 15 mg/kg q3 weeks. Pts unable to swallow used alternative drug preparation (ADP; crushed vemurafenib, suspension cobimetinib). Primary objective is to determine whether the tx in cohorts 1-3 leads to improved overall survival (OS). The trial was designed to enroll 36 pts but we are reporting early due to positive findings. Response rate (RR) was measured by RECISTv1.1. Median OS was estimated by Kaplan-Meier method. cfDNA and biopsy were obtained at baseline, course 2 and progression. Pts were allowed to undergo surgery and radiation while on trial. Results: From August 2017-January 2020, 34 ATC pts were enrolled in cohorts 1-3 and 9 in cohort 4. Cohort 3 closed early for futility. 3 pts had ADP. Median follow-up time was 7.51 mos (range: 0.43 – 27.37). Median OS in cohorts 1-3 was 18.23 mos (CI 10.45-NE) and 1-year OS was 67% (95%CI: 45%, 82%). See table. Response rate (RR) in cohort 1 was 71%: CR 1/17 (6%), PR 11/17 (65%), SD 4/17 (23%), 1 never restaged; in cohort 2 RR was 7%: PR 1/14 (7%), SD 7/14 (50%), PD 4/14 (29%), 2 died early. 8 (24% of cohort 1-3) pts had complete tumor resection after tx with VCA (n = 7) or CA (n = 1); all but 1 of these pts are alive. AEs as expected. cfDNA data will be reported at meeting. Conclusions: Atezolizumab + vemurafenib/cobimetinib for BRAF-mutated or + cobimetinib for NF1/2 or RAS-mutated ATC is effective, as evidenced by the long OS in these pts (13 mos &gt; historical control). A significant number of patients, particularly in cohort 1, were able to undergo complete tumor resection due to a favorable response to tx. Clinical trial information: NCT03181100 . [Table: see text]
Phase II study of amrubicin for previously treated patients with malignant pleural mesothelioma.
Authors: Kazumasa Akagi, Takaya Ikeda, Katsumi Nakatomi, Hirokazu Taniguchi, Midori Shimada, Hiroshi Gyotoku, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroaki Senju, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae
Journal: Journal of Clinical Oncology (2020)

e21095 Background: Malignant pleural mesothelioma (MPM) is a rare disease with few effective treatments and poor prognosis. Although pemetrexed (PEM) and cisplatin for the first-line treatment, and nivolumab for the second-line are considered as the standard treatment for patients with unresectable disease, these effects are still limited. There are no other effective agents for second-line treatment, although PEM-based regimens, vinorelbine, gemcitabine are recommended by some guidelines. Novel therapeutic strategies for the treatment of MPM are urgently required. Amrubicin (AMR) is a chemically synthesized anthracycline-based anticancer drug that inhibits cell growth by stabilizing the cleavable complex via topoisomerase II. The same anthracycline; adriamycin was one of the key drugs for MPM prior to the appearance of PEM, but its efficacy against MPM has not been revealed. Thus, we planned a phase II study of AMR therapy for previously treated MPM. Methods: Eligibility criteria were previously treated patients with unresectable MPM, performance status 0-2, age≦75, and adequate hematological, hepatic and renal function. Patients were treated with injections of AMR 35 mg/m 2 on days 1, 2, and 3. The treatments were repeated every 3-4 weeks. The primary endpoint was the response rate (RR), the secondary endpoints were safety, progression-free survival time (PFS), overall survival time (OS). Results: Although the number of target cases was 32 cases, case registration was delayed and evaluation was performed with 10 cases enrolled. Patients' characteristics were as follows: male/female = 9/1; performance status 0/1/2 = 0/10/0; median age (range) = 67 (49-73); histology epithelial/sarcomatoid/mixed = 4/3/3; stage (IMIG) I/II/III/IV/postoperative recurrence = 0/1/4/4/1. RR was 10.0% (1/10), median PFS was 1.6 months and median OS was 6.6 months. Disease control rate was 50.0% (5/10). Adverse events of Grade 3 or 4 were neutropenia 60.0% (6/10), thrombocytopenia 10.0% (1/10), anemia 10.0% (1/10), febrile neutropenia 10.0% (1/10), and pneumonia 10.0% (1/10). Conclusions: This study demonstrated that AMR therapy for previously treated MPM was tolerable. The efficacy was limited, but may be effective in some cases. Clinical trial information: UMIN000006381 .
Effect of mammography screening frequency on false-positive biopsy rates and detection of local recurrence among breast cancer survivors.
Authors: Julia E McGuinness, Haley Manley, Sarah Yuan, Samuel M Pan, Ziyi Zhao, Richard D. Ha, Jeanine M Genkinger, Katherine D. Crew
Journal: Journal of Clinical Oncology (2020)

7016 Background: Current guidelines recommend that women with a history of early-stage breast cancer treated with breast-conserving therapy (BCT) continue screening mammography after treatment. One strategy is semi-annual ipsilateral mammography for the first 3 years after diagnosis, when risk of local recurrence is highest. However, a potential harm of more frequent screening is false-positive breast biopsy. We examined the association between screening frequency and rates of false-positive biopsy and local recurrence among breast cancer survivors. Methods: We conducted a retrospective cohort study at Columbia University Irving Medical Center (CUIMC) in New York, NY, of women diagnosed with stage 0-III breast cancer from 2007 to 2017, who were treated with BCT and had at least 2 screening mammograms at CUIMC within the first 3 years after diagnosis. Demographic and clinical information were collected from the electronic health record. Frequency of mammography screening was defined as the median interval between two consecutive mammograms (every 6 months vs. yearly). False-positive biopsy and local recurrence were identified by review of breast pathology reports. A false-positive biopsy was defined as a breast biopsy without evidence of invasive or non-invasive cancer. Descriptive statistics and logistic regression models were conducted to examine relationships between covariates and either false-positive biopsy or local recurrence. Results: In our study cohort (n = 1404), the median age at breast cancer diagnosis was 61 years (range, 24-94), including 45% white, 14% black, 32% Hispanic, and 8% Asian. Eighty percent of women had screening mammography of the ipsilateral breast every 6 months during the first 3 years after diagnosis. Comparing women who screened every 6 months vs. yearly, there was no difference in local recurrence rates (4.0% vs. 4.1%), including screen-detected and invasive recurrences, but a higher rate of false-positive biopsy (13.5% vs. 7.5%). In multivariable analysis, women who screened every 6 months had about a 2-fold increased risk of having a false-positive biopsy (OR 1.93; 95% CI 1.17-3.19); no other factors were significantly associated with false-positive biopsy. Conclusions: We observed that women with early-stage breast cancer treated with BCT who underwent more frequent screening mammography had more false-positive breast biopsies, but no difference in local recurrence rates. Future studies are needed to determine optimal screening strategies for breast cancer survivors.